A3650
阿米卡星 水合物
aminoglycoside antibiotic
别名:
N 1 - [(S)-4-氨基-2-羟基丁酰基] 卡那霉素 A
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C22H43N5O13 · xH2O
化学文摘社编号:
分子量:
585.60 (anhydrous basis)
UNSPSC Code:
51281632
NACRES:
NA.85
PubChem Substance ID:
EC Number:
253-538-5
Beilstein/REAXYS Number:
1445422
MDL number:
产品名称
阿米卡星 水合物, aminoglycoside antibiotic
InChI key
DTSOZYYWEZJFSS-XTHCGPPUSA-N
InChI
1S/C22H43N5O13.H2O/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21;/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36);1H2/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+;/m0./s1
SMILES string
O.NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O
biological source
synthetic
form
powder
color
white to almost white
antibiotic activity spectrum
Gram-negative bacteria
mycobacteria
mode of action
protein synthesis | interferes
storage temp.
2-8°C
Quality Level
Application
阿米卡星水合物用于对诸如 结核分枝杆菌 和 嗜艾利希体 等微生物的抗菌敏感性研究。
Biochem/physiol Actions
阿米卡星通过与 30S 核糖体亚基结合，诱导 mRNA 误读，从而抑制细菌蛋白质合成。干扰 tRNA 从 A 位点到 P 位点的移位。
General description
化学结构：氨基糖苷类
Other Notes
保存于密闭容器内，置于干燥通风处。
Packaging
5G
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
法规信息
涉药品监管产品
此项目有
H W Horowitz et al.
Antimicrobial agents and chemotherapy, 45(3), 786-788 (2001-02-22)
Human granulocytic ehrlichiosis is a recently described disease caused by an obligate intracellular gram-negative organism recently named Ehrlichia phagocytophila. To expand our knowledge of the susceptibility of E. phagocytophila, we tested six New York State isolates for susceptibility to 12
G J Alangaden et al.
Antimicrobial agents and chemotherapy, 42(5), 1295-1297 (1998-05-21)
An A1400G mutation of the rrs gene was identified in Mycobacterium tuberculosis (MTB) strain ATCC 35827 and in 13 MTB clinical isolates resistant to amikacin-kanamycin (MICs, >128 microg/ml). High-level cross-resistance may result from such a mutation since MTB has a
Hessel Van der Weide et al.
Antibiotics (Basel, Switzerland), 9(3) (2020-03-07)
Background: Recent scientific reports on the use of high dose tigecycline monotherapy as a "drug of last resort" warrant further research into the use of this regimen for the treatment of severe multidrug-resistant, Gram-negative bacterial infections. In the current study
Meenu Sharma et al.
Journal of clinical microbiology, 49(12), 4112-4116 (2011-10-15)
The purpose of this study was to establish a standardized protocol for second-line antimicrobial susceptibility testing of Mycobacterium tuberculosis using the Bactec MGIT 960 system in Canadian laboratories. Four Canadian public health laboratories compared the susceptibility testing results of 9
Sophia B Georghiou et al.
PloS one, 7(3), e33275-e33275 (2012-04-06)
Rapid molecular diagnostics for detecting multidrug-resistant and extensively drug-resistant tuberculosis (M/XDR-TB) primarily identify mutations in Mycobacterium tuberculosis (Mtb) genes associated with drug resistance. Their accuracy, however, is dependent largely on the strength of the association between a specific mutation and
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持